SMC^® Human GFAP High Sensitivity Immunoassay Kit

The SMC^® Human GFAP High Sensitivity Immunoassay Kit contains all reagents required to perform the assay. This assay takes advantage of a standard immunoassay workflow configured in a standard plate format. Assay protocols are similar to existing sandwich ELISA methods with two key differences: 1) Elution buffer disrupts the sandwich, separating the labeled detection antibody for quantification. 2) The Erenna and SMCxPRO^® immunoassay systems detect analytes using Single Molecule Counting (SMC^®) technology.
Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein produced notably by astrocytes during CNS development, and functions in astrocyte regeneration, plasticity, and also contributes to function of the blood brain barrier. GFAP is a potential biomarker in a number of neurodegenerative diseases as well as in traumatic brain injury. There is much interest today in measuring GFAP levels in low abundance, because not only does it make it possible to evaluate this protein as a blood biomarker, but also enables researchers to study the downregulation of GFAP in therapeutic research. The new SMC^® Human GFAP High Sensitivity Immunoassay Kit enables accurate measurement of this protein in human serum, plasma, and cerebrospinal fluid, harnessing the power of the SMCxPRO^® ultrasensitive immunoassay system.

Specificity to the following species samples were tested with the follow results:
Non Human Primate – 100%
Mouse – 100%
Rat – 100%
Canine – 100%
Feline – 100%

Note: This assay was tested for cross-reactivity with Ventimin, NFL, UCHL1 and total Tau. No cross-reactivity was detected with any of these analytes.

The sensitivity of the Single Molecule Counting SMC^® technology gives the SMC^® Human GFAP High Sensitivity Immunoassay Kit unparalleled performance in the quantification of Human GFAP in human serum, plasma, and CSF.

This new streamline kit has the following features:

• Improved options for sample prep and incubation
• Lyophilization protein standard for uniform shipping and storage condition
• Increased reagent volumes to accommodate automation
• Able to achieve assay specifications on both SMCxPRO^® and Erenna.

Research Category:
Neuroscience
neurological

Research Sub-Category:
Alzheimer′s Disease
Aging, Nervous System
Neurodegenerative Diseases
Neurofilament & Neuron Metabolism
Neuronal & Glial Markers
Neuroregenerative Medicine
Neuroscience

Minimum of 4 serum samples spiked with average recovery of 118% with a range of 113-123%
Minimum of 4 plasma samples spiked with average recovery of 115% with a range of 110-119%
Minimum of 5 CSF samples spiked with average recovery of 101% with a range of 95-106%

SMC is a registered trademark of Singulex

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.